RT Journal Article
SR Electronic
T1 The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1739
OP 1745
DO 10.21873/anticanres.14127
VO 40
IS 3
A1 KOSUKE UEDA
A1 NAOYUKI OGASAWARA
A1 SATORU YONEKURA
A1 YOSHIHIRO MATSUNAGA
A1 RYUJI HOSHINO
A1 HIROFUMI KUROSE
A1 KATSUAKI CHIKUI
A1 KEIICHIRO UEMURA
A1 MAKOTO NAKIRI
A1 KIYOAKI NISHIHARA
A1 MITSUNORI MATSUO
A1 SHIGETAKA SUEKANE
A1 TSUKASA IGAWA
YR 2020
UL http://ar.iiarjournals.org/content/40/3/1739.abstract
AB Background/Aim: The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. Patients and Methods: A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed. Results: High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, prior nephrectomy (p=0.0013) and CRP/Alb ratio (p=0.0020) were independent prognostic factors for OS. Conclusion: CRP/Alb and NLR/Alb ratios are useful and independent prognostic biomarkers in patients with advanced RCC treated with molecular targeted therapy.